LUDIVINA VIGIL: Open Payments
NPI 1659675312 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$539 in 21 payments from 11 companies in 2025. Trend: 2023 $209 · 2024 $104 · 2025 $539
Food & beverage: $539
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 4 | $108 |
| AstraZeneca Pharmaceuticals LP | 3 | $81 |
| Janssen Biotech, Inc. | 3 | $71 |
| ABBVIE INC. | 2 | $52 |
| PharmaEssentia USA Corporation | 2 | $45 |
| Eisai Inc. | 2 | $44 |
| Merck Sharp & Dohme LLC | 1 | $34 |
| SOBI, INC | 1 | $32 |
| Incyte Corporation | 1 | $27 |
| Novartis Pharmaceuticals Corporation | 1 | $24 |
Products named: ENHERTU, DARZALEX, AYVAKIT, WAYRILZ, BESREMI, Lenvima, KEYTRUDA, Vonjo.
Industry payments across FL — which companies pay providers there.
